{"filing":{"accession_number":"0001104659-26-074292","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tm2618041d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926074292/tm2618041d1_8k.htm"},"events":[{"id":11189,"run_id":9809,"accession_number":"0001104659-26-074292","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"PTC Therapeutics announced the pricing of a $500 million convertible notes offering (with an additional $50 million option), which will result in shares of common stock issuable upon conversion. The notes are unregistered securities sold pursuant to an exemption from Securities Act registration. This is a material dilutive issuance that raises substantial capital and creates future equity dilution through conversion rights.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7721,"accession_number":"0001104659-26-074292","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"PTC Therapeutics announced the pricing of a $500 million convertible notes offering (with an additional $50 million option), which will result in shares of common stock issuable upon conversion. The notes are unregistered securities sold pursuant to an exemption from Securities Act registration. This is a material dilutive issuance that raises substantial capital and creates future equity dilution through conversion rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:01:06.698841+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7721,"accession_number":"0001104659-26-074292","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"PTC Therapeutics announced the pricing of a $500 million convertible notes offering (with an additional $50 million option), which will result in shares of common stock issuable upon conversion. The notes are unregistered securities sold pursuant to an exemption from Securities Act registration. This is a material dilutive issuance that raises substantial capital and creates future equity dilution through conversion rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:01:06.698841+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-06-16"}]}